The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

被引：137

作者：

Geisler, Christian H. ^{[1
]}

Kolstad, Arne ^{[2
]}

Laurell, Anna ^{[3
]}

Raty, Riikka ^{[4
]}

Jerkeman, Mats ^{[5
]}

Eriksson, Mikael ^{[5
]}

Nordstrom, Marie ^{[6
]}

Kimby, Eva ^{[6
]}

Boesen, Anne Marie ^{[7
]}

Nilsson-Ehle, Herman ^{[8
]}

Kuittinen, Outi ^{[9
]}

Lauritzsen, Grete F. ^{[2
]}

Ralfkiaer, Elisabeth

Ehinger, Mats ^{[5
]}

Sundstrom, Christer ^{[3
]}

Delabie, Jan ^{[2
]}

Karjalainen-Lindsberg, Marja-Liisa ^{[4
]}

Brown, Peter

Elonen, Erkki ^{[4
]}

机构：

[1] Rigshosp, Dept Hematol 4042, DK-2100 Copenhagen, Denmark

[2] Norwegian Radium Hosp, Oslo, Norway

[3] Univ Uppsala Hosp, Uppsala, Sweden

[4] Univ Helsinki, Cent Hosp, Helsinki, Finland

[5] Univ Lund Hosp, S-22185 Lund, Sweden

[6] Karolinska Inst, Stockholm, Sweden

[7] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark

[8] Sahlgrenska Hosp, Gothenburg, Sweden

[9] Oulu Univ Hosp, Oulu, Finland

来源：

BLOOD | 2010年 / 115卷 / 08期

关键词：

PROGRESSION-FREE SURVIVAL; RITUXIMAB; MCL; THERAPY; RESCUE; KI67;

D O I：

10.1182/blood-2009-08-236570

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680. (Blood. 2010;115:1530-1533)

引用

页码：1530 / 1533

页数：4

共 24 条

[1]

Chan WC, 1997, BLOOD, V89, P3909

[2] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[3]

CHIAPELLA A, 2009, HEMATOLOGY S, V2, P395

[4] Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade lymphoma Study Group [J].

Determann, Olaf ;

Hoster, Eva ;

Ott, German ;

Bernd, Heinz Wolfram ;

Loddenkemper, Christoph ;

Hansmann, Martin Leo ;

Barth, Thomas E. F. ;

Unterhalt, Michael ;

Hiddemann, Wolfgang ;

Dreyling, Martin ;

Klapper, Wolfram .

BLOOD, 2008, 111 (04) :2385-2387

[5] Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network [J].

Dreyling, M ;

Lenz, G ;

Hoster, E ;

Van Hoof, A ;

Gisselbrecht, C ;

Schmits, R ;

Metzner, B ;

Truemper, L ;

Reiser, M ;

Steinhauer, H ;

Boiron, JM ;

Boogaerts, MA ;

Aldaoud, A ;

Silingardi, V ;

Kluin-Nelemans, HC ;

Hasford, J ;

Parwaresch, R ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2005, 105 (07) :2677-2684

[6] Proliferation Predicts Failure-free Survival in Mantle Cell Lymphoma Patients Treated With Rituximab Plus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine [J].

Garcia, Mar ;

Romaguera, Jorge E. ;

Inamdar, Kedar V. ;

Rassidakis, George Z. ;

Medeiros, L. Jeffrey .

CANCER, 2009, 115 (05) :1041-1048

[7] Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group [J].

Geisler, Christian H. ;

Kolstad, Arne ;

Laurell, Anna ;

Andersen, Niels S. ;

Pedersen, Lone B. ;

Jerkeman, Mats ;

Eriksson, Mikael ;

Nordstrom, Marie ;

Kimby, Eva ;

Boesen, Anne Marie ;

Kuittinen, Outi ;

Lauritzsen, Grete F. ;

Nilsson-Ehle, Herman ;

Ralfkiaer, Elisabeth ;

Akerman, Mans ;

Ehinger, Mats ;

Sundstrom, Christer ;

Langholm, Ruth ;

Delabie, Jan ;

Karjalainen-Lindsberg, Marja-Liisa ;

Brown, Peter ;

Elonen, Erkki .

BLOOD, 2008, 112 (07) :2687-2693

[8] Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue [J].

Hartmann, Elena ;

Fernandez, Veronica ;

Moreno, Victor ;

Valls, Joan ;

Hernandez, Luis ;

Bosch, Francesc ;

Abrisqueta, Pau ;

Klapper, Wolfram ;

Dreyling, Martin ;

Hoster, Eva ;

Mueller-Hermelink, Hans Konrad ;

Ott, German ;

Rosenwald, Andreas ;

Campo, Elias .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (30) :4966-4972

[9] A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma [J].

Hoster, Eva ;

Dreyling, Martin ;

Klapper, Wolfram ;

Gisselbrecht, Christian ;

van Hoof, Achiel ;

Kluin-Nelemans, Hanneke C. ;

Pfreundschuh, Michael ;

Reiser, Marcel ;

Metzner, Bernd ;

Einsele, Hermann ;

Peter, Norma ;

Jung, Wolfram ;

Woermann, Bernhard ;

Ludwig, Wolf-Dieter ;

Duehrsen, Ulrich ;

Eimermacher, Hartmut ;

Wandt, Hannes ;

Hasford, Joerg ;

Hiddemann, Wolfgang ;

Unterhalt, Michael .

BLOOD, 2008, 111 (02) :558-565

[10] Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study [J].

Hsi, Eric D. ;

Jung, Sin-Ho ;

Lai, Raymond ;

Johnson, Jeffrey L. ;

Cook, James R. ;

Jones, Dan ;

Devos, Sven ;

Cheson, Bruce D. ;

Damon, Lloyd E. ;

Said, Jonathan .

LEUKEMIA & LYMPHOMA, 2008, 49 (11) :2081-2090

← 1 2 3 →